Sir, We read with interest the multicentre Italian study by Frasca`et al. [1] that confirms that a proportion of patients (6/51) with thin glomerular basement membrane disease (TBMD) have an underlying type IV collagen mutation that may not always be benign.
In the 'subjects and methods' section they state that the measurements of glomerular basement membrane was performed by the method published by us [2] . However, our work involved a comparison between the Orthagonal Intercepts Method (OIM) and our modification of direct measurement (MDM) method, applying it on two glomeruli rather than one. Frasca`et al. [1] do not state which of the two (or both) methods was used in their study. We found that although the MDM method is acceptable for diagnosing TBMD, on average the values were about 80 nm less than those obtained with OIM. As one of the patients described by Frasca`was only 8 years old we would also remind readers that basement membrane thickness is age related [3] .
5/18 patients with suggestive family histories or 6/51 in the overall group had collagen IV mutations suggesting that other genes involved in the production or turnover of glomerular basement membrane are likely to be equally important in the pathogenesis of this variant/ disease.
It would also be interesting to know if any of the ultrastructural lesions correlated with collagen IV mutations.
Conflict of interest statement. None declared. 1 Reply Sir, In our study on thin glomerular basement membrane disease (TBMD) we used the modified direct measurement method as proposed by Das et al. [1] . We are aware that by this method the authors found values that were on average about 80 nm less than those obtained by using the Orthagonal Intercepts Method. Thus, as specified in our report, the three laboratories involved in the study had their own standards for 'normal' GBM thickness to be used as a control measurement. We did not find any correlation between the presence of collagen IV mutations and the ultrastructural appearance of the GBM, which was characterized by a uniform thinning without additional alterations, and represented the main criteria for inclusion in the study. Discussion. Infection related to intravenous catheters remains a major source of morbidity and mortality in patients treated with chronic haemodialysis [2] . Osteomyelitis complicates up to 14% of these cases [3] . S. epidermidis is a common cause of bacteraemia in renal units [1] . In Case 1 we report sternoclavicular osteomyelitis-a previously unreported but serious complication of what is considered to be a benign infection [4] . The incidence of M. tuberculosis has increased by 11% nationally (over 5 years) and by 71% in London (over 10 years) [5] . Chronic renal failure is known to cause immune dysregulation and is a risk factor for developing active TB. However, there are no reports of M. tuberculosis causing catheter exit site infection in this or other patient groups. Despite advances in renal replacement therapy there is no intervention proven to improve the immune status of dialysis patients or mitigate the infection risks associated with longtem catheters. AVFs remain the gold standard for dialysis access due to improved patient survival [6] . With increasing use of tunnelled lines in immunocompromised subjects unusual infections are likely to be a growing phenomenon in dialysis units. Drug interaction between sevelamer and furosemide Sir, Sevelamer hydrochloride (Renagel Õ ) is a calcium-free nonabsorbable phosphate-binding cationic polymer marketed for the treatment of hyperphosphataemia in patients undergoing renal function replacement [1] .
Furosemide is a loop diuretic. Large doses of furosemide have been employed as an adjunct to other therapies in patients with acute and chronic renal failure. In some patients, the use of furosemide may permit a slightly more liberal fluid intake. This is very important for the quality of life of these patients.
A 64-year-old female on haemodialysis thrice weekly started with sevelamer for hyperphosphataemia. Her urine production was 950 ml/day with furosemide 250 mg twice daily. Upon starting sevelamer, 800 mg with breakfast, 800 mg at lunchtime and 1600 mg with dinner, she noticed that her urine production stopped within 24 h after taking the first sevelamer capsule. After sevelamer withdrawal, her urine production increased within 24 h to her previous level. Her urine production stopped again within 24 h after resumption of sevelamer and increased after withdrawal. Unfortunately, we do not know if the patient gained weight or if there were any blood pressure fluctuations during the time the urine production stopped.
At present the patient takes furosemide 500 mg once daily in the morning and sevelamer twice daily 1600 mg at lunch and dinner. Her urine production is stable as before.
Our case provides evidence for an interaction between the loop diuretic furosemide and the phosphate-binding polymer sevelamer, confirmed by rechallenge. The mechanism of the interaction is probably a physical binding of furosemide to sevelamer in the gastrointestinal tract, diminishing the absorption of furosemide. An alternative
